Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Medistem, Orcrist collaborate to augment stem cell activity
June 2008
SHARING OPTIONS:

CALGARY, Alberta­—Medistem Laboratories Inc. and Orcrist Bio Inc. recently announced a collaborative agreement to co-develop therapies based upon Medistem's newly discovered Endometrial Regenerative Cell population and ORC's recently licensed HYC750 technology.

"If one takes a step back and looks at the field of regenerative medicine, the first phase will be clinical entry of stem cell types, which is already occurring; the second phase will be development of pharmaceutical agents that augment activity of stem cells," says Thomas Ichim, Ph.D., CEO of Medistem. "Orcrist has strongly positioned themselves as developers of stem cell augmenting agents. Their lead compound HYC750 is in late preclinical development, thus providing a potential synergistic agent to technologies we are currently developing."

Orcrist President and CEO Gary Voncina notes, "Medistem was recently recognized with the 'Top Publication of 2007' by BioMed Central and is recognized as a leader in stem cell research. The potential for collaboration around Orcrist's stem cell mobilization technology and Medistem's core intellectual property could lead to ground-breaking advancements in the commercialization of stem cell products." DDN

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.